A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Jingyi Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Mycetoma, Madurella, Drug Repositioning, NF-kappa B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erasmus University, CSC, Dutch Research Council.
Abstract (Originalsprache)
Background
Mycetoma caused by Madurella mycetomatis (eumycetoma) is a neglected tropical disease that forms tumorous lesions in the subcutaneous tissue. The current standard treatment for eumycetoma consists of antifungal treatment combined with surgery, with limited success rates. Due to lack of investment, there are currently no large drug discovery programmes for mycetoma. Repurposing screening can therefore offer an effective and economical way to identify drugs that can be effective in eumycetoma treatment. Therefore, in this study we determined the in vitro activity and in vivo efficacy of 5631 compounds present in the Oncode Drug Repurposing library.
Methods
In total, 5631 drugs from the Oncode Drug Repurposing library were screened for in vitro activity against M. mycetomatis using a CLSI-based in vitro susceptibility assay and CellTiter-Glo as a viability dye. Compounds that inhibited the metabolic activity were tested for in vivo activity in M. mycetomatis-infected Galleria mellonella larvae.
Results
Twenty-eight compounds out of the 5631 drugs were able to inhibit the metabolic activity of M. mycetomatis at 2 µM. Seventeen of the 28 compounds were azoles and 2 were toxic to G. mellonella and therefore not screened further. Two from the remaining 9 compounds, bay117085 (log-rank, P = 0.0494) and IMD-0354 (log-rank, P = 0.0043), prolonged the survival of M. mycetomatis-infected larvae. Both compounds were designed as NF-κB inhibitors.
Conclusions
NF-κB inhibitors bay117085 and IMD-0354 were able to prolong the survival of M. mycetomatis-infected larvae.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
- Organic Chemistry Laboratory, University Bayreuth, Bayreuth, Germany.
ORCID-Profile: Jingyi Ma, Wendy W J van de Sande
Förderung
- Erasmus University
- CSC
- Dutch Research Council
Zitieren
APA
Ma, J., van Doodewaerd, B. R., Biersack, B., Verbon, A., Geurink, P. P., & van de Sande, W. W. J. (2025). A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf369
Vancouver
Ma J, van Doodewaerd BR, Biersack B, Verbon A, Geurink PP, van de Sande WWJ. A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf369
BibTeX
@article{Ma2025,
author = {Ma, Jingyi and van Doodewaerd, Bjorn R and Biersack, Bernhard and Verbon, Annelies and Geurink, Paul P and van de Sande, Wendy W J},
title = {A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf369}
}
EUVIMED